SCHEMBL4007094

SCHEMBL4007094

Nc1ccc2[nH]nc(C(=O)Nc3ccccc3)c2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 8/20 0.72
CDK2 P24941 4/20 0.72
CCNA2 P20248 1/20 0.72
CCNA1 P78396 1/20 0.72
JAK2 O60674 2/20 0.64
JAK1 P23458 2/20 0.64
CSNK2A1 P68400 6/20 0.63
DYRK3 O43781 1/20 0.63
MAP4K4 O95819 1/20 0.63
CDK1 P06493 1/20 0.63
MARK3 P27448 1/20 0.63
CLK2 P49760 1/20 0.63
GSK3B P49841 1/20 0.63
CSNK1G2 P78368 1/20 0.63
CDK5 Q00535 1/20 0.63
MAP4K2 Q12851 1/20 0.63
PRKAA1 Q13131 1/20 0.63
CAMK2B Q13554 1/20 0.63
CAMK2G Q13555 1/20 0.63
CAMK2D Q13557 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4531693 0.88 FLT3 (0.55) FLT3CDK2CCNA2CCNA1JAK2
SCHEMBL28775976 0.86 DYRK1A (0.66) FLT3CDK2CCNA2CCNA1CSNK2A1
SCHEMBL5945718 0.85 FLT3 (0.70) FLT3CDK2CCNA2CCNA1JAK2
SCHEMBL5945795 0.85 FLT3 (0.71) FLT3CDK2CCNA2CCNA1JAK2
SCHEMBL30912934 0.85 FLT3 (0.70) FLT3CDK2CCNA2CCNA1JAK2
SCHEMBL5945798 0.85 FLT3 (0.70) FLT3CDK2CCNA2CCNA1JAK2
SCHEMBL4153422 0.85 FLT3 (0.70) FLT3CDK2CCNA2CCNA1JAK2
SCHEMBL5945808 0.85 FLT3 (0.70) FLT3CDK2CCNA2CCNA1JAK2
SCHEMBL30398090 0.84 FLT3 (1.00) FLT3CDK2CCNA2CCNA1CSNK2A1
SCHEMBL951125 0.84 FLT3 (1.00) FLT3CDK2CCNA2CCNA1CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135589-A1 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors ASTEX TECHNOLOGY, INC. (GB) 2006-06-22 US claimed
JP-2006500348-A 2006-01-05 JP claimed
EP-1534685-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS Astex Technology Limited (GB) 2005-06-01 EP claimed
WO-2004014864-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-02-19 WO claimed
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 US disclosed
US-20060135589-A1 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors ASTEX TECHNOLOGY, INC. (GB) 2006-06-22 US disclosed
EP-1534685-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS Astex Technology Limited (GB) 2005-06-01 EP disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
WO-2005014554-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2005-02-17 WO disclosed
EP-1487803-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY Aventis Pharma S.A. (FR) 2004-12-22 EP disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 US disclosed
WO-2004014864-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-02-19 WO disclosed
WO-2003078402-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY AVENTIS PHARMA S.A. (FR) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 FLT3 58/4885CDK2 10/4885CCNA2 633/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 FLT3 75/4885CDK2 28/4885CCNA2 629/4885
US-20060135589-A1 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors CCNC, CDK1, CDK7 FLT3 164/4885CDK2 5/4885CCNA2 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.